Alzheon Inc.
Clinical trials sponsored by Alzheon Inc., explained in plain language.
-
New Alzheimer's pill shows promise in slowing cognitive decline for High-Risk group
Disease control CompletedThis Phase 3 trial tested whether an oral medication called ALZ-801 could slow Alzheimer's progression in people with early-stage disease who carry two copies of the APOE4 gene, which increases risk. 325 participants took either the drug or a placebo twice daily for 78 weeks whil…
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Apr 02, 2026 08:42 UTC
-
Alzheimer's pill targets brain plaques in High-Risk patients
Disease control CompletedThis study tested whether an oral medication called ALZ-801 could affect biological markers of Alzheimer's disease in people with early symptoms who carry specific genetic risk factors (APOE4 gene). The 84 participants took the pill twice daily for up to four years while research…
Phase: PHASE2 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC